Your browser doesn't support javascript.
Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity.
Maeda, Yuichi; Motooka, Daisuke; Kawasaki, Takahiro; Oki, Hiroya; Noda, Yoshimi; Adachi, Yuichi; Niitsu, Takayuki; Okamoto, Shota; Tanaka, Kentaro; Fukushima, Kiyoharu; Amiya, Saori; Hara, Reina; Oguro-Igashira, Eri; Matsuki, Takanori; Hirata, Haruhiko; Takeda, Yoshito; Kida, Hiroshi; Kumanogoh, Atsushi; Nakamura, Shota; Takeda, Kiyoshi.
  • Maeda Y; Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Motooka D; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Kawasaki T; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.
  • Oki H; WPI Immunology Frontier Research Center, Osaka University, Suita, Japan.
  • Noda Y; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.
  • Adachi Y; Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
  • Niitsu T; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Okamoto S; National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
  • Tanaka K; Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
  • Fukushima K; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Amiya S; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Hara R; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Oguro-Igashira E; Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Matsuki T; WPI Immunology Frontier Research Center, Osaka University, Suita, Japan.
  • Hirata H; WPI Immunology Frontier Research Center, Osaka University, Suita, Japan.
  • Takeda Y; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Kida H; Department of Host Defense, Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan.
  • Kumanogoh A; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Nakamura S; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Takeda K; Department of Respiratory Medicine, Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
BMC Infect Dis ; 22(1): 572, 2022 Jun 24.
Article in English | MEDLINE | ID: covidwho-1910275
ABSTRACT

BACKGROUND:

The impact of SARS-CoV-2 infection on the gut fungal (mycobiota) and bacterial (microbiota) communities has been elucidated individually. This study analyzed both gut mycobiota and microbiota and their correlation in the COVID-19 patients with severe and mild conditions and follow-up to monitor their alterations after recovery.

METHODS:

We analyzed the gut mycobiota and microbiota by bacterial 16S and fungal ITS1 metagenomic sequencing of 40 severe patients, 38 mild patients, and 30 healthy individuals and reanalyzed those of 10 patients with severe COVID-19 approximately 6 months after discharge.

RESULTS:

The mycobiota of the severe and mild groups showed lower diversity than the healthy group, and in some, characteristic patterns dominated by a single fungal species, Candida albicans, were detected. Lower microbial diversity in the severe group was observed, but no differences in its diversity or community structure were detected between the mild and healthy groups. The microbiota of the severe group was characterized by an increase in Enterococcus and Lactobacillus, and a decrease in Faecalibacterium and Bacteroides. The abundance of Candida was positively correlated with that of Enterococcus in patients with COVID-19. After the recovery of severe patients, alteration of the microbiota remained, but the mycobiota recovered its diversity comparable to that of mild and healthy groups.

CONCLUSION:

In mild cases, the microbiota is stable during SARS-CoV-2 infection, but in severe cases, alterations persist for 6 months after recovery.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Microbiota / Gastrointestinal Microbiome / COVID-19 Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: S12879-022-07358-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Microbiota / Gastrointestinal Microbiome / COVID-19 Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: S12879-022-07358-7